10-Q: Climb Bio Reports Q2 Loss Amid R&D Surge

Climb Bio, a clinical-stage biotech, reported increased operating losses and significant R&D expenses in Q2 2025, driven by pipeline advancements, while maintaining a cash runway through 2027.

Summary

• Net loss for the three months ended June 30, 2025, was $8.7 million, compared to $54.9 million for the same period in 2024, with the prior year including a $51.7 million acquired in-process research and development expense.
• Net loss for the six months ended June 30, 2025, was $29.4 million, compared to $56.6 million for the same period in 2024.
• Research and development expenses significantly increased to $6.6 million for Q2 2025 (from $1.0 million in Q2 2024) and $23.9 million for the six months ended June 30, 2025 (from $2.1 million in H1 2024), primarily due to budoprutug clinical trial activities and manufacturing, and a $9.0 million upfront payment for CLYM116.
• Cash and cash equivalents decreased from $87.2 million at December 31, 2024, to $22.7 million at June 30, 2025.
• Total cash, cash equivalents, and marketable securities stood at $187.4 million as of June 30, 2025.
• The company anticipates its current capital will fund operations through 2027.
• Progress was made in clinical programs: FDA clearance for Phase 2 budoprutug in primary membranous nephropathy (pMN) in March 2025, and IND clearances for budoprutug in systemic lupus erythematosus (SLE) in October 2024 and immune thrombocytopenia (ITP) in March 2025.
• A subcutaneous (SC) formulation of budoprutug showed high bioavailability and favorable tolerability in non-clinical data in H1 2025, with a Phase 1 clinical trial in Australia anticipated to start in coming weeks.
• CLYM116, an anti-APRIL monoclonal antibody, is undergoing IND-enabling studies, with preclinical data expected in September 2025 and an IND/CTA submission anticipated in H2 2025.
• Material weaknesses in internal control over financial reporting were identified, related to insufficient accounting personnel and lack of formal policies, but management believes remediation efforts are making substantial progress.

Sentiment

Score: 4

Explanation: The company is in a high-burn, early-stage biotech phase with significant R&D expenses and increasing operational cash outflow. While clinical programs are progressing and there's a stated cash runway through 2027, the substantial decrease in cash and the explicit need for future financing, coupled with identified material weaknesses in internal controls and intense industry competition, indicate a high-risk profile. The positive clinical advancements are offset by the financial challenges and inherent uncertainties of drug development.

Positives

• Secured FDA clearance for a Phase 2 clinical trial of budoprutug in primary membranous nephropathy (pMN) in March 2025, with first patient dosing anticipated in the second half of 2025.
• Received FDA clearance for Investigational New Drug (IND) applications for budoprutug in systemic lupus erythematosus (SLE) in October 2024 and immune thrombocytopenia (ITP) in March 2025, with patient enrollment and dosing underway.
• Obtained orphan drug designation for budoprutug for the treatment of pMN, which may provide financial incentives and market exclusivity.
• Advanced a subcutaneous (SC) formulation of budoprutug, demonstrating high bioavailability and favorable tolerability in non-clinical data in the first half of 2025, with a Phase 1 clinical trial in Australia cleared for initiation.
• Entered into an exclusive license agreement for CLYM116, expanding the pipeline of B-cell targeted therapeutics for immune-mediated diseases.
• Maintained a cash, cash equivalents, and marketable securities balance of $187.4 million as of June 30, 2025, which is estimated to fund operations through 2027.

Negatives

• Incurred significant operating losses since inception, with an accumulated deficit of $259.3 million as of June 30, 2025.
• Net cash used in operating activities significantly increased to $26.6 million for the six months ended June 30, 2025, compared to $2.5 million for the same period in 2024, indicating a higher cash burn rate.
• Cash and cash equivalents decreased substantially from $87.2 million at December 31, 2024, to $22.7 million at June 30, 2025.
• Identified material weaknesses in internal control over financial reporting, specifically lacking sufficient accounting personnel and formal policies/procedures, which could affect financial reporting accuracy.
• No product revenue generated since inception, and profitability is not expected in the foreseeable future.
• Reliance on future financing is anticipated, with no assurances of availability on acceptable terms, which could force delays or termination of product development programs.

Risks

• Incurred significant losses since inception and anticipate substantial losses for the foreseeable future, may never achieve or maintain profitability.
• Inability to access capital when needed could force delays, reductions, or termination of product development programs, commercialization efforts, or other operations.
• No current source of product revenue and may never become profitable.
• Future success is primarily dependent on the regulatory approval and commercialization of product candidates, budoprutug and CLYM116.
• Estimates of market opportunity and forecasts of market growth for product candidates may prove inaccurate.
• Preliminary, initial, or interim clinical trial results may change as more data becomes available.
• Preclinical and clinical development is a lengthy, complex, and expensive process with an uncertain outcome; early trial results may not predict later success.
• Drug development is highly uncertain, and inability to successfully develop and commercialize product candidates, or significant delays, could harm the business.
• Significant competition in an environment of rapid technological change, with competitors potentially achieving regulatory approval first or developing superior therapies.
• Reliance on third parties to conduct, supervise, and monitor preclinical studies and clinical trials, with risks of non-performance or missed deadlines.
• Reliance on third parties, including single-source suppliers and manufacturers, for critical materials and manufacturing, risking supply disruptions.
• Compromised or interrupted information technology systems or data, or those of third parties, could lead to adverse consequences including regulatory actions, litigation, and reputational harm.
• Heavy reliance on certain in-licensed patents and other intellectual property rights, with potential need to acquire or license additional rights.
• Uncertainty that pending patent applications will result in issued patents, or that obtained patent protection will be sufficiently broad.
• Identified material weaknesses in internal control over financial reporting, which if unremediated, could affect accurate and timely financial reporting.
• The trading price of common stock has been and may continue to be volatile, potentially leading to substantial losses for purchasers.
• Product candidates may cause adverse events or undesirable side effects, delaying or preventing regulatory approval or limiting commercial profile.
• Difficulties enrolling and/or retaining patients in clinical trials could delay or adversely affect clinical development activities.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses, regulatory reform, government shutdowns) could hinder timely approval.
• Enacted and future legislation (e.g., ACA, IRA, OBBBA) may increase difficulty and cost of obtaining marketing approval and commercialization, and affect pricing.
• Business operations and relationships are subject to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare regulations, with potential for substantial penalties for non-compliance.
• Stringent and evolving U.S. and foreign data privacy and security laws (e.g., GDPR, CCPA, new U.S. laws on data transfer to countries of concern like China) pose risks of investigations, litigation, and fines.
• Designations like Breakthrough Therapy, Fast Track, Priority Review, and PRIME may not lead to faster development or approval.
• Accelerated approval by the FDA, even if granted, may not lead to faster development or approval and does not guarantee ultimate marketing approval.
• Inability to realize the full benefits associated with orphan drug designation, including market exclusivity.
• Product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.
• Conducting clinical trials at sites outside the U.S. carries risks, including non-acceptance of data by the FDA or additional delays and expense.
• Inability to obtain regulatory approval in foreign jurisdictions would prevent marketing product candidates outside the U.S.
• Inability to establish future collaborations may alter future development and commercialization plans.
• Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact business and operating results.
• Reliance on third parties requires sharing trade secrets, increasing risk of discovery or misappropriation.
• Involvement in lawsuits to protect or enforce intellectual property could be expensive, time-consuming, and unsuccessful.
• Inability to protect intellectual property rights throughout the world.
• Failure to identify relevant third-party patents or incorrect interpretation of their relevance, scope, or expiration.
• Failure to comply with obligations in license agreements could lead to loss of license rights.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Changes in patent law could diminish the value of patents.
• Inability to protect the confidentiality of trade secrets.
• Inability to protect and enforce trademarks and trade names.
• Intellectual property rights may not address all potential threats.
• Failure to attract and retain management and other key personnel.
• Misconduct by employees, independent contractors, consultants, or other third parties.
• International operations expose the company to business, regulatory, political, operational, financial, pricing, and reimbursement risks.
• May not be able to utilize a significant portion of net operating loss carryforwards due to ownership changes.
• Failure to manage acquisitions, investments, licenses, or other strategic alliances, or integrate them, could adversely affect operating results, dilute stockholders, or increase debt.
• Concentration of common stock ownership among existing executive officers, directors, and principal stockholders may limit new investors' influence and reduce public float.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Claims for indemnification by directors and officers may reduce available funds.
• Securities litigation or stockholder derivative litigation could divert management attention and harm the business.
• Limited equity research analyst coverage could cause stock price and trading volume to decline.
• Unfavorable global economic conditions could adversely affect business, financial condition, stock price, and results of operations.
• Inability to maintain adequate insurance coverage.
• Changes in tax laws or regulations could seriously harm the business.

Future Outlook

The company estimates its current cash, cash equivalents, and marketable securities will be sufficient to fund operations through 2027. It anticipates needing to raise substantial additional financing in the future to advance and expand its research pipeline, conduct preclinical studies and clinical trials, develop and commercialize any approved products, and explore other pipeline opportunities. The company expects research and development expenses to increase substantially as it progresses its product candidates and expands corporate infrastructure. It also plans to initiate a Phase 1 clinical trial for the subcutaneous formulation of budoprutug in Australia in the coming weeks, with initial clinical data expected in the first half of 2026. Preclinical data for CLYM116 is expected in September 2025, and an IND or CTA submission for CLYM116 in IgAN is anticipated in the second half of 2025.

Management Comments

• We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for the millions of patients living with immune-mediated diseases.
• We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development paths and have the potential to address significant unmet needs.
• We believe we are well-positioned to advance budoprutug across three distinct opportunity sets in immune-mediated disease: primarily IgG4-mediated diseases, primarily single organ IgG1-3 mediated diseases and complex systemic diseases.
• We are advancing our Phase 2 clinical trial of budoprutug in pMN and anticipate dosing our first patient in the second half of 2025.
• We continue to activate sites and are enrolling and dosing patients in both trials (budoprutug in SLE and ITP).
• We anticipate initiating this trial (SC budoprutug Phase 1) in the coming weeks and expect to have initial clinical data in the first half of 2026.
• We expect to report preclinical data from the CLYM116 program in September 2025, and we anticipate submitting an IND or CTA for CLYM116 in IgAN in the second half of 2025.
• We believe our existing cash, cash equivalents and marketable securities of $187.4 million as of June 30, 2025 will be sufficient to meet our projected operating requirements for at least the next twelve months from the filing date of these unaudited condensed consolidated financial statements, and the Company anticipates that it will need to raise substantial financing in the future to fund its operations.
• We believe we have made substantial progress toward achieving the effectiveness of our internal control over financial reporting and disclosure controls and procedures.

Industry Context

The biopharmaceutical industry is characterized by rapid technological change, significant competition, and high R&D costs. Climb Bio's focus on immune-mediated diseases, particularly with monoclonal antibodies like budoprutug (anti-CD19) and CLYM116 (anti-APRIL), aligns with a growing area of therapeutic development. The regulatory landscape is becoming more complex, with new requirements for clinical trial diversity (FDORA) and ongoing debates/litigation over drug pricing (IRA, Executive Orders), which could impact market access and profitability. The industry also faces increasing scrutiny on data privacy and security, and geopolitical tensions (e.g., U.S.-China trade policies, BIOSECURE Act) could disrupt global supply chains and collaborations, particularly for companies relying on foreign manufacturers or partners.

Comparison to Industry Standards

• Climb Bio's accumulated deficit of $259.3 million and lack of product revenue are typical for a clinical-stage biotechnology company, as significant capital is required for R&D before commercialization.
• The cash runway through 2027, based on current operating plans, is a reasonable timeframe for a biotech at this stage, providing stability for ongoing clinical programs, though additional financing will be necessary.
• The increase in R&D expenses to $23.9 million for H1 2025 reflects active progression of clinical programs (budoprutug) and new licensing agreements (CLYM116), which is consistent with a company advancing its pipeline.
• The identified material weaknesses in internal control over financial reporting, while concerning, are not uncommon for companies transitioning from private to public, and the stated remediation efforts are standard industry practice.
• The competitive landscape for CD19-targeted therapies includes established players like Amgen (UPLIZNA for neuromyelitis optica spectrum disorder and IgG4-related disease, BLA filed for generalized myasthenia gravis) and other companies developing naked monoclonal antibodies (IASO Biotherapeutics), non-depleting antibodies (Eli Lilly), antibody-drug conjugates (AbbVie), bispecific T-cell engagers (Cullinan Therapeutics, Zenas BioPharma, Roche, Merck), and CAR-T/CAR-NK therapies (Novartis, Bristol Myers Squibb, Cabaletta Bio, Kyverna Therapeutics, Nkarta). Climb Bio's budoprutug will face intense competition in these areas.
• For APRIL-targeted therapies, CLYM116 will compete with products from Otsuka (sibeprenlimab, BLA filed), Novartis (zigakibart), Jade Biosciences (JADE-001), Vertex Pharmaceuticals (povetacicept), and Vera Therapeutics (atacicept), as well as CD38-targeted therapies (Biogen, Takeda Pharmaceuticals) and degraders (Biohaven). The market for IgAN is becoming increasingly competitive.
• The company's reliance on third-party CROs and CDMOs is a common industry model for clinical-stage biotechs without in-house manufacturing or extensive clinical operations infrastructure.

Management Changes

Corporate Governance

Legal Proceedings

• Not party to any material legal matters or claims as of June 30, 2025.
• The company's ability to develop and market new product candidates may be impacted by ongoing litigation challenging the FDA's approval of other drug products (e.g., mifepristone), which could lead to delays or undermine approvals.
• The company is monitoring ongoing litigation related to the Inflation Reduction Act's (IRA) Medicare Drug Price Negotiation Program, which could affect future pricing and reimbursement for its products if approved.

Related Party Transactions

• The acquisition of Tenet Medicines, Inc. on June 27, 2024, was from a company majority-owned by funds affiliated with RA Capital Management, L.P., which beneficially owned approximately 43.9% of Climb Bio's common stock prior to the acquisition.
• The technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (Mabworks) for CLYM116, entered into on January 8, 2025, involves a Chinese corporation and includes obligations for Mabworks to conduct preclinical studies and provide clinical supply of CLYM116.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future capital raises (e.g., at-the-market offering), stock price volatility, and impact from material weaknesses in internal controls. Long-term value depends on successful clinical development and commercialization.
• **Employees:** Increased headcount in R&D and G&A functions, but also risks related to potential layoffs if financing is not secured or programs are delayed/terminated. New Chief Business Officer hired, but COO's departure noted.
• **Customers (Future):** Development of potential best-in-class therapeutics for immune-mediated diseases aims to address significant unmet medical needs, offering new treatment options if approved.
• **Suppliers/Manufacturers:** Continued reliance on third-party and single-source suppliers/manufacturers for critical materials and services, posing risks of supply disruption and increased costs.
• **Creditors:** The company's significant accumulated deficit and reliance on future financing indicate a need for careful financial management to meet obligations.

Next Steps

• Initiate Phase 1 clinical trial in healthy volunteers with the subcutaneous (SC) formulation of budoprutug in Australia in the coming weeks.
• Expect initial clinical data from the SC budoprutug Phase 1 trial in the first half of 2026.
• Anticipate dosing the first patient in the Phase 2 clinical trial of budoprutug in primary membranous nephropathy (pMN) in the second half of 2025.
• Continue activating sites and enrolling/dosing patients in Phase 1b clinical trials for budoprutug in systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP).
• Expect to report preclinical data from the CLYM116 program in September 2025.
• Anticipate submitting an Investigational New Drug (IND) application or Clinical Trial Application (CTA) for CLYM116 in immunoglobulin A nephropathy (IgAN) in the second half of 2025.
• Continue evaluating the Kv7 program (ETX-123 and ETX-155) and seeking a partner for further development.
• Continue remediation efforts to address identified material weaknesses in internal control over financial reporting, including hiring qualified personnel, implementing improved policies/processes, and financial systems.

Key Dates

Recommendation

Climb Bio is a clinical-stage biotechnology company with promising pipeline assets (budoprutug and CLYM116) addressing significant unmet needs in immune-mediated diseases. The company has a cash runway through 2027, providing near-term operational stability for its ongoing and planned clinical trials. However, it faces substantial financial challenges, including a high cash burn rate from operations and an explicit need for significant future financing. The identified material weaknesses in internal controls, while being addressed, add a layer of operational risk. The highly competitive landscape and inherent uncertainties of drug development, coupled with regulatory and geopolitical risks, make this a high-risk investment. For a seasoned investor, holding the stock might be justified if they believe in the long-term potential of the pipeline and are comfortable with the significant risks and the likelihood of future dilution. It is not a 'buy' due to the current financial position and speculative nature, nor a 'sell' given the clinical progress and cash runway.

Keywords

Biotechnology, Clinical-stage, Immune-mediated diseases, Budoprutug, CLYM116, Monoclonal antibody, Anti-CD19, Anti-APRIL, Primary membranous nephropathy, Immune thrombocytopenia, Systemic lupus erythematosus, IgA nephropathy, Drug development, Clinical trials, SEC filing, 10-Q, Financial results, Biopharmaceutical, Orphan drug, Intellectual property, Regulatory approval, Cash burn, Liquidity, Corporate governance